Pharmacielo Ltd (PCLO)
TSX Venture Exchange · Canada · prices in CAD · close of 20 Oct 2026
Key indicators
| Last close | CAD 0.050 |
|---|---|
| 52-week range | 0.035 – 0.165 |
| Return, 1 month / 3 months | −9.1% / −16.7% |
| Return, 1 year / 3 years | +11.1% / −78.3% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 176.2% |
| Worst drawdown (1 year) | -70.4% |
| Average daily value traded | 0.00M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PharmaCielo Ltd is a cannabis company based in Colombia that cultivates and processes cannabis for medicinal and pharmaceutical purposes. It produces cannabis extracts, oils and derivatives at its facilities in the country and supplies pharmaceutical and wellness markets, including customers abroad. The company manages its own cultivation and extraction operations, focusing on producing standardized cannabis ingredients for use in medicines and other regulated products.
Pharmacielo Ltd trades under the code PCLO on the TSX Venture Exchange in Canada, with its price quoted in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pharmacielo Ltd (PCLO) trades on the TSX Venture Exchange in Canada. It last closed at CAD 0.050 on 20 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 1,015 of 1,500 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.1% and over the last three months it fell 16.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on TSX Venture Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -25.5% | ||
| From 52-week high | -63.0% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -16.7% | ||
| 6-month return | 11.1% | ||
| 12-month return, skipping the last month | 22.2% | ||
| Stability (higher is calmer) | 17 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 176.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -70.4% | ||
| Liquidity | 46 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M CAD | ||
| Zero-volume days | 16.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −9.1% |
| 3 months | −16.7% |
| 6 months | +11.1% |
| 1 year | +11.1% |
| 3 years | −78.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 0.057 / 0.067 |
|---|---|
| Golden / death cross (60 days) | Death, 33 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.004 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on TSX Venture Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.